Feb. 2 at 7:24 PM
$RVPH $NERV asked grok to a compare of RVPH and NERV lead drugs and their prospects.. here is the result;
Overall Prospects Looking Ahead
• RVPH: Prospects remain strong long-term (superior drug profile,
$1-2B potential), but near-term risks elevated—funding needs, dilution pressure, Nasdaq delisting threat (~
$0.50 price), and delayed catalysts. Stock volatile; 37% YTD gain in early 2026 faded on update. Success hinges on RECOVER-2 execution and partnership potential post-start.
• NERV: More de-risked operationally (cash secured, clear FDA path); prospects solid for niche approval (~
$500M-1B peak). Less funding drama, but narrower market limits blockbuster upside. Recent KOL event (Feb 3, 2026) reinforced protocol confidence.
Bottom line: Brilaroxazine edges as the better drug scientifically, but NERV has a funding/timeline advantage post-RVPH’s setback. Both face 2026-2028 binary risks in a competitive schizophrenia space (e.g., Cobenfy traction).
